Jump to main content
Jump to site search


The transition to magic bullets – transition state analogue drug design

Author affiliations

Abstract

In the absence of industry partnerships, most academic groups lack the infrastructure to rationally design and build drugs via methods used in industry. Instead, academia needs to work smarter using mechanism-based design. Working smarter can mean the development of new drug discovery paradigms and then demonstrating their utility and reproducibility to industry. The collaboration between Vern Schramm's group at the Albert Einstein College of Medicine, USA and Peter Tyler at the Ferrier Research Institute at The Victoria University of Wellington, NZ has refined a drug discovery process called transition state analogue design. This process has been applied to several biomedically relevant nucleoside processing enzymes. In 2017, Mundesine®, conceived using transition state analogue design, received market approval for the treatment of peripheral T-cell lymphoma in Japan. This short review looks at a brief history of transition state analogue design, the fundamentals behind the development of this process, and the success of enzyme inhibitors produced using this drug design methodology.

Graphical abstract: The transition to magic bullets – transition state analogue drug design

Back to tab navigation

Publication details

The article was received on 25 Jul 2018, accepted on 24 Aug 2018 and first published on 28 Aug 2018


Article type: Review Article
DOI: 10.1039/C8MD00372F
Citation: Med. Chem. Commun., 2018, Advance Article
  •   Request permissions

    The transition to magic bullets – transition state analogue drug design

    G. B. Evans, V. L. Schramm and P. C. Tyler, Med. Chem. Commun., 2018, Advance Article , DOI: 10.1039/C8MD00372F

Search articles by author

Spotlight

Advertisements